Wang, Shujing
Qi, Changsong
Ding, Jin
Li, Dan
Zhang, Miao
Ji, Congcong
Jiang, Fangli
Teng, Fei
Yu, Jie
Qian, Xueming
Wang, Feng
Shen, Lin
Gao, Jing
Yang, Zhi
Zhang, Cheng
Zhu, Hua
Funding for this research was provided by:
National Natural Science Foundation of China (82171980, 82171973, 82102091, 82072728)
Beijing Hospitals Authority’ Ascent Plan (DFL20191102)
Beijing Millions of Talent Projects A level funding (No. 2019A38)
The Pilot Project (4 th Round) to Reform Public Development of Beijing Municipal Medical Research Institute (2021-1)
Article History
Received: 21 December 2022
Accepted: 14 April 2023
First Online: 26 April 2023
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The clinical study was approved by the Ethics Committee of Peking University Cancer Hospital (2021KT57) and was registered at ClinicalTrial.gov (NCT04883970).
: Informed consent was obtained from all individual participants included in the study.
: None declared. Intellectual property protection has been filed by Suzhou Transcenta Therapeutics Company and Peking University Cancer Hospital.